# JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

> **NCT06973564** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jacobio Pharmaceuticals Co., Ltd.** · enrollment: 294 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** JAB-23E73
- **DRUG:** JAB-23E73
- **DRUG:** JAB-23E73

## Key facts

- **NCT ID:** NCT06973564
- **Lead sponsor:** Jacobio Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2027-11
- **Final completion:** 2028-02
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973564, "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06973564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*